
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Lee, Dae Ho, Liu, Yunpeng, YVolume:
16
Langue:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(15)00121-7
Date:
August, 2015
Fichier:
PDF, 395 KB
english, 2015